Daily Cosmetic Research Analysis
Analyzed 25 papers and selected 3 impactful papers.
Summary
Analyzed 25 papers and selected 3 impactful articles.
Selected Articles
1. Decoding patient preferences: key drivers in selecting thyroid cancer surgery- a discrete choice experiment.
In a registered discrete choice experiment of 271 papillary thyroid carcinoma patients, recurrence risk was the dominant driver of surgical preference, with additional willingness to pay for scarless approaches such as TOETVA. Patients would pay ~¥201,410 to reduce recurrence from 10% to 1% and ~¥19,141 to move the scar internally, highlighting the need to integrate oncologic risk and cosmetic priorities in preoperative counseling.
Impact: Quantifies patient trade-offs between oncologic safety and cosmetic outcomes with monetized preferences, directly informing shared decision-making and surgical counseling.
Clinical Implications: Discuss recurrence risk reduction alongside cosmetic benefits of approaches like TOETVA, using WTP estimates to personalize counseling; prioritize oncologic safety while acknowledging cosmetic preferences that vary by demographics.
Key Findings
- Recurrence risk was the strongest non-financial driver of surgical choice (reported β = 8.18).
- Patients were willing to pay ~¥201,409.60 to reduce recurrence from 10% to 1%.
- Patients were willing to pay ~¥19,141.14 to change scar location from external to internal (scarless).
- Cosmetic concerns varied across demographic subgroups, indicating heterogeneity in preferences.
Methodological Strengths
- Pre-registered design (ChiCTR2300069048) with mixed logit analysis of discrete choice data.
- Adequate sample size (n=271) enabling estimation of willingness-to-pay and trade-offs across multiple attributes.
Limitations
- Stated preferences in hypothetical scenarios may not fully reflect real-world choices (hypothetical bias).
- Generalizability may be limited to similar healthcare and cultural contexts; cost estimates are in JPY.
Future Directions: Conduct multicenter DCEs across diverse settings, link stated preferences to revealed choices and outcomes, and embed preference data into decision aids comparing TOETVA and open surgery.
OBJECTIVE: With the growing application of the transoral endoscopic thyroidectomy vestibular approach (TOETVA) for papillary thyroid carcinoma (PTC), understanding patient preferences is critical to improving communication and supporting informed decision-making. This study aimed to identify key factors influencing surgical choices. METHOD: A discrete choice experiment was conducted with patients diagnosed with PTC who were scheduled for thyroidectomy. Participants evaluated hypothetical surgical scenarios varying in six attributes: incision location, incision size, recurrence rate, operative duration, complication rate, and cost. Preferences and willingness to pay (WTP) were analyzed using a mixed logit model. RESULTS: A total of 271 patients were included in this study. Patients demonstrated a strong preference for surgical options with lower recurrence rates and scarless approaches. They were willing to pay an additional ¥201,409.60 to reduce the recurrence rate from 10% to 1% and ¥19,141.14 to change the surgical scar location from external to internal. The recurrence rate emerged as the most crucial non-financial factor (β = 8.18, CONCLUSION: Recurrence risk is the primary driver of surgical preference in PTC patients, followed by cosmetic outcomes. Additionally, postoperative cosmetic concerns varied across different demographic groups. These findings highlight the need for surgeons to consider patient-specific values during preoperative consultations to enhance shared decision-making. CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/showproj.html?proj=191809, identifier ChiCTR2300069048.
2. Human-Relevant In Vitro Skin Models: From Regulatory-Validated Platforms to Emerging Technologies for Translational Dermatology.
This review synthesizes the state of human-relevant in vitro skin models spanning reconstructed epidermis/full-thickness equivalents to vascularized, immune-competent, organoid-based, and microbiome-integrated systems. It identifies regulatory gaps and lays out priorities for standardization and benchmarking to accelerate predictive, ethical safety testing for cosmetics and dermatologic therapeutics.
Impact: Provides a comprehensive, translational roadmap for adopting advanced skin models that can reduce animal testing while improving human relevance in cosmetic safety and dermatology.
Clinical Implications: Adoption of validated and next-generation human skin models can improve preclinical prediction of irritation, sensitization, and efficacy, informing safer cosmetic formulations and prioritizing candidates for clinical testing.
Key Findings
- Reconstructed human epidermis and full-thickness skin equivalents are established for regulatory and research use, with variants supporting pigmentation and microbiome.
- Ex vivo human skin platforms complement 3D models, enabling human-tissue–based assessment.
- Emerging platforms include vascularized/perfused, immune-competent, appendage-containing organoid models, and microbiome-integrated systems.
- Key gaps include lack of standardization, scalability challenges, and need for clinical translation and benchmarking.
Methodological Strengths
- Comprehensive survey of both commercially available and emerging platforms across regulatory and research contexts.
- Integrates functional dimensions (pigmentation, immunity, vasculature, microbiome) highlighting mechanistic relevance.
Limitations
- Narrative review without formal PRISMA methodology; no quantitative meta-analysis or benchmarking.
- Heterogeneity of models and endpoints limits direct comparability and evidence grading.
Future Directions: Establish standardized performance benchmarks and interlaboratory ring trials, enhance immune/vascular integration and appendage fidelity, and link in vitro readouts to clinical endpoints using multi-omics and AI.
The rapid advancement of human-relevant in vitro skin models has been driven by increasingly stringent regulatory restrictions on animal testing and the growing recognition that conventional animal and two-dimensional cell culture systems fail to accurately predict human skin biology and clinical outcomes. Three-dimensional reconstructed human skin models, ex vivo human skin platforms, and next-generation bioengineered systems have been recognized as critical tools for dermatological research, cosmetic safety assessment, and pharmaceutical development. This review focuses on commercially available in vitro human skin models currently used in regulatory and research settings, as well as emerging technologies under active development. We provide an overview of reconstructed human epidermis and full-thickness skin equivalents, functional variants incorporating pigmentation and microbiome support, and ex vivo human skin models derived from surgical tissues. Additionally, we discuss cutting-edge platforms, including vascularized and perfused skin models, immune-competent skin constructs, organoid-based appendage-containing models, and microbiome-integrated platforms. Furthermore, we highlight current limitations, regulatory gaps, and future directions for standardization, scalability, and clinical translation. Collectively, advanced human skin models are expected to significantly enhance dermatological research by enabling predictive, ethical, and mechanistically informative testing strategies that bridge the gap between in vitro experimentation and clinical outcomes.
3. Toxicity assessment of nanocosmetics: techniques and necessity for safety evaluation.
This narrative review consolidates toxicity assessment methods for nanocosmetics, emphasizing how nano-specific physicochemical properties affect dermal penetration and biological interactions. It delineates regulatory gaps and calls for standardized, nano-tailored characterization and exposure-informed testing to ensure consumer safety.
Impact: Addresses a rapidly expanding class of cosmetic products with unique risk profiles, providing a practical framework for toxicity testing and regulatory strengthening.
Clinical Implications: Formulators and clinicians can use these frameworks to anticipate irritation/sensitization risks, guide pre-market testing, and counsel patients on nano-enabled products.
Key Findings
- Nano-specific size, surface, and composition properties modulate dermal penetration and systemic uptake, altering toxicity profiles.
- Current skin and ocular safety assessments span in vitro, in vivo, and alternative methods targeting irritation, sensitization, cytotoxicity, genotoxicity, and embryotoxicity.
- Regulatory gaps persist regarding nano-specific characterization and dermal exposure assessment; standardized testing batteries are needed.
Methodological Strengths
- Integrates peer-reviewed evidence with regulatory documents for applied relevance.
- Covers multiple toxicity endpoints and methodological modalities (in vitro, in vivo, alternative methods).
Limitations
- Narrative synthesis without PRISMA-compliant systematic methods; limited quantitative comparison across materials.
- Heterogeneity of nanomaterials and exposure scenarios limits generalizability and risk quantification.
Future Directions: Develop harmonized nano-specific characterization standards, exposure metrics, and validated alternative testing batteries; couple with real-world exposure studies and post-market surveillance.
BACKGROUND: The application of nanotechnology to cosmetic formulations has gained recognition due to enhanced stability, efficacy, and aesthetic appeal of products. These engineered nanomaterials are purposefully produced to possess nano-specific properties, whereas traditional microsized particles are manufactured primarily to improve formulation texture. However, their increasing use for beautification and medicinal purposes has raised serious concerns regarding nanocosmetic toxicity. This review highlights the distinct physical and chemical characteristics of nanocosmetics that influence skin penetration, cellular interactions, and potential systemic uptake following dermal application, emphasizing the need for comprehensive toxicity evaluation. METHODS: This review compiles appropriate peer-reviewed literature from various scientific databases along with regulatory documents from authoritative sources. The review focuses on toxicity assessment approaches for nanocosmetics, including in vitro, in vivo, and alternative methods. Special emphasis is placed on skin irritation and sensitization models, cytotoxicity assays, genotoxicity assessments, and embryonic toxicity tests for evaluating nanocosmetic-associated toxicity. RESULTS: The review summarizes current approaches for evaluating the skin and ocular safety of nanocosmetic ingredients and discusses the influence of nano-specific physicochemical properties on dermal penetration and biological interactions. It also identifies existing data gaps in current regulatory frameworks, particularly concerning nano-specific safety assessment, physicochemical characterization, and dermal exposure evaluation. These findings highlight the importance of adopting comprehensive and standardized toxicity testing strategies for nanocosmetics. CONCLUSIONS: The increasing application of nanotechnology in cosmetic formulations necessitates robust toxicity evaluation to ensure consumer safety. Strengthening regulatory frameworks by incorporating nano-specific safety assessment and exposure evaluation is essential to promote the safe use of nanomaterials in cosmetic products while supporting their continued development and commercialization.